|
Bystrova A.A., Khalimov Yu.Sh., Shodikulova G.Z., Atoev T.T., Lisker A.V.
Correlation between non-alcoholic fatty liver disease and intestinal microbiota dysbiosis
|
№8 / 2024
|
|
Dora S.V., Khalimov Yu.Sh., Mekhtiev S.N., Lisker A.V., Zimina M.V., Semikova G.V., Volkova A.R., Cherebillo I.V., Polyakova Yu.V.
Correlation between estrogen deficiency and non-alcoholic fatty liver disease in female patients
|
№8 / 2024
|
|
Prikhodko V.A., Okovityi S.V.
Gliflozins as remedies for correction of non-alcoholic fatty liver disease neurological complications. Part 2
|
№5 / 2024
|
|
Prikhodko V.A., Okovityi S.V.
Gliflozins as remedies for correction of neurological complications of non-alcoholic fatty liver disease. Part 1
|
№4 / 2024
|
|
Pankova E.D., Chulkov V.S., Ektova N.A.
Prognostication of non-alcoholic fatty liver disease in people of young age
|
№2 / 2024
|
|
Turkina S.V., Statsenko M.E., Kosivtsova M.A., Titarenko M.N., Tyshchenko I.A.
Patient with non-alcoholic fatty liver disease at care encounter of a therapist: Aspects of diagnostics and treatment
|
№9 / 2023
|
|
Tarasova L.V., Tsyganova Yu.V.
Therapy of non-alcoholic liver steatosis as an important factor in the prevention of complications of non-alcoholic fatty liver disease
|
№7 / 2023
|
|
Prikhodko V.A., Okovity S.V., Kulikov A.N.
Gliflozins in non-alcoholic fatty liver disease: Perspectives of use outside diabetes, cardiac and nephroprotection
|
№7 / 2023
|
|
Aryamkina O.L., Dobrynina I.Yu., Biek A.Yu., Saitov A.R., Tarasova L.V., Zapevalov A.V., Grishmanovsky P.V., Grishmanovskaya O.N.
Possibilities for diagnostics of non-alcoholic fatty liver disease in patients with metabolically associated comorbid pathology
|
№7 / 2023
|
|
|
№3 (приложение) / 2023
|
|
|
№3 (приложение) / 2023
|
|
|
№3 (приложение) / 2023
|
Русский
